Optimization of drug treatment of acromegaly (clinical and morphological comparison)
- 作者: Pronin E.V.1, Antsiferov M.B1, Alekseeva T.M1, Urusova L.S2, Lapshina A.M2, Mokrysheva N.G2
-
隶属关系:
- Endocrinological Dispensary of the Moscow Healthcare Department
- Reference Center for Pathomorphological, Immunohistochemical and Radiological Research Methods, National Medical Research Center for Endocrinology
- 期: 卷 29, 编号 4 (2022)
- 页面: 44-52
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/320971
- DOI: https://doi.org/10.18565/pharmateca.2022.4.44-52
- ID: 320971
如何引用文章
详细
全文:
![受限制的访问](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
作者简介
Evgeniy Pronin
Endocrinological Dispensary of the Moscow Healthcare Department
Email: r-wp@mail.ru
Endocrinologist
M. Antsiferov
Endocrinological Dispensary of the Moscow Healthcare Department
T. Alekseeva
Endocrinological Dispensary of the Moscow Healthcare Department
L. Urusova
Reference Center for Pathomorphological, Immunohistochemical and Radiological Research Methods, National Medical Research Center for Endocrinology
A. Lapshina
Reference Center for Pathomorphological, Immunohistochemical and Radiological Research Methods, National Medical Research Center for Endocrinology
N. Mokrysheva
Reference Center for Pathomorphological, Immunohistochemical and Radiological Research Methods, National Medical Research Center for Endocrinology
参考
- Akirov A., Asa S.L., Amer L., et al. The Clinicopathological Spectrum of Acromegaly. J. Clin Med. 2019;8(11):1962. Doi: 10.3390/ jcm8111962.
- Lopes M.B.S. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521-35. doi: 10.1007/s00401-017-1769-8.
- Syro L.V., Rotondo F., Serna C.A., et al. Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary Pituitary 2017;20(1):84-92. doi: 10.1007/s11102-016-0748-8.
- Cuevas-Ramos D., Carmichael J.D., Cooper O., et al. A structural and functional acromegaly classification. J. Clin Endocrinol Metab. 2015;100(1):122-31. doi: 10.1210/jc.2014-2468.
- Asa S.L., Kucharczyk W., Ezzat S. Pituitary acromegaly: not one disease. Endocr Relat Cancer. 2017;24(3):1- 4. doi: 10.1530/ERC-16-049.
- Bollerslev J., Heck A., Olarescu N.C. Management of endocrine disease: individualised management of acromegaly. Eur J. Endocrinol. 2019;181(2):57-71. doi: 10.1530/EJE-19-0124.
- Agrawal N., loachimescu A.G. Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review. Pituitary. 2020;23(5):582-94. doi: 10.1007/s11102-020-01063-x.
- Alquraini H., Schneider M.D.P., Mirakhur B., Barcan A. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naive to somatostatin-receptor ligands: analysis of three multicenter clinical trials. Pituitary. 2018;21(3):283-89. doi: 10.1007/s11102-018-0867-5.
- Giustina A., Barkhoudarian G., Beckers A., et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord Actions. 2020;21(4):667-678. doi: 10.1007/s11154-020-09588-z.
- Puig-Domingo M., Gil J., Sampedro-Nunez M., et al. Molecular profiling for acromegaly treatment: a validation study. Endocr Relat Cancer. 2020;27:375-89. doi: 10.1530/ERC-18-0565.
- Sahakian N., Castinetti F., Brue N., Cuny N. Current and Emerging Medical Therapies in Pituitary Tumors. J. Clin Med. 2022;11(4):955. Doi: 10.3390/ jcm11040955.
- Gomes-Porras M., Cardenas-Salas J., Alvares-Escola C. Somatostatin Analogs in Clinical Practice: A Review. J. MolSci. 2020;21(5):1682. Doi: 10.3390/ ijms21051682.
- Puig-Domingo M., Marazuela M. Precision medicine in the treatment of acromegaly Minerva Endocrinol. 2019;44(2):169- 75. doi: 10.23736/S0391-1977.18.02937-1
- Puig-Domingo M., Bernabeu I., Pico A., etal. Pasireotide in the Personalized Treatment of Acromegaly. Front Endocrinol. (Lausanne). 2021;12:648411. doi: 10.3389/fendo.2021.648411.
- Ku C.R., Melnikov V., Zhang Z., Lee E.J. Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality? Endocrinol Metab. (Seul). 2020;35(2):206-16. Doi: 10.3803/ EnM.2020.35.2.206.
- Kocak B., Durmaz E.S., Kadioglu P., et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur Radiol. 2019;29:2731-9. doi: 10.1007/s00330- 018-5876-2.
- Rass L., Rahvar A-H., Matschke J., etal. Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy? Hormones (Athens). 2022;21(1):79-89. doi: 10.1007/s42000-021-00327-w.
- Villa C., Vasiljevic A., Jaffrain-Rea M.L., et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch. 2019;475:687-92. doi: 10.1007/s00428- 019-02655-0.
- Lloyd L.V., Osamura R.Y., Cloppel G., et al. Tumours of the pituitary gland in WHO classification of tumours of endocrine organs. WHO press, Geneva, 2017. P. 19-24.
- Casar-Borota O., Heck A., Schulz S., et al. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide. Clin Endocrinol Metab. 2013;98(11):E1730-39. Doi: 10.1210/ jc.2013-2145.
- Ezzat S., Caspar-Bell G.M., Chik C.L., etal. Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline. Endocr Pract. 2019;25(4):379- 93. doi: 10.4158/EP-2018-0500.
- Анциферов М.Б., Пронин Е.В., Алексеева Т.М., Пронин В.С. Предикторы эффективности медикаментозной терапии акромегалии (по данным Московского регистра). Фарматека. 2020;27(4):50-56. doi: 10.18565/ pharmateca.2022.0.50-56.
- Coopmans E., Korevaar TJ.M., van Meyel S.W.F., et al. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. J. Clin Endocrinol Metab. 2020;105(9):dgaa387. doi: 10.1210//clinem/ dgaa387.
- Fleseriu M., Biller B.M.K., Freda PU., et al. A Pituitary Society update to acromegaly management guidelines. Pituitary, 2021;24(1):1-13. Doi. org/10.1007/s11102-020-01091-7.
- Kasuki L., Wildemberg L.E., Gadelha M. Management of endocrine disease: Personalized medicine in the treatment of acromegaly. Eur J. Endocrinol. 2518;178(3):R89-155. doi: 10.1530/EJE-17-1006.
- Gadelha M.R., Wildemberg L.E., Kasuki L. The Future of Somatostatin Receptor Ligands in Acromegaly. J. Clin Endocrinol Metab. 2022;107(2):297-308. doi: 10.1210/olinem/dgab726.
- Nista F., Corica G., Castelletti L., et al. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. Front Endocrinol. (Lausanne). 2021;12:677919. doi: 10.3389/fendo.2021.677919.
- Wildemberg L.E., da Silva Camacho A.H., Miranda R.L., et al. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. J Clin Endocrinol Metab. 2021;16,106(7):2047-56. doi: 10.1210/clinem/dgab125
- Liu W., Xie L., He M., et al. Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues. Int J. Endocrinol. 2017;2017:9606985. doi: 10.1155/2017/9606985.
补充文件
![](/img/style/loading.gif)